©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2016; 4(2): 49-55
Published online Feb 16, 2016. doi: 10.12998/wjcc.v4.i2.49
Published online Feb 16, 2016. doi: 10.12998/wjcc.v4.i2.49
Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C
Monica Salvi, Laura Macaluso, Cecilia Luci, Carlo Mattozzi, Giovanni Paolino, Yvonne Aprea, Stefano Calvieri, Antonio Giovanni Richetta, Department of Dermatology and Venerology, Policlinico Umberto I, 00161 Rome, Italy
Author contributions: All authors contributed to the acquisition of data, writing and revision of the manuscript.
Institutional review board statement: This case report was exempt from the Institutional Review Board Standards of the Department of Dermatology at La Sapienza University of Rome.
Informed consent statement: The patient involved in this study gave his written informed consent authorizing use and disclosure of his protected health information.
Conflict-of-interest statement: All the authors have not conflict of interest to declare.
Correspondence to: Monica Salvi, MD, Department of Dermatology and Venerology, Policlinico Umberto I, viale del Policlinico 155, 00161 Rome, Italy. monica.slv@hotmail.it
Telephone: +39-333-2576530 Fax: +39-06-4462104
Received: April 23, 2015
Peer-review started: April 24, 2015
First decision: September 8, 2015
Revised: October 20, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: February 16, 2016
Processing time: 277 Days and 15.4 Hours
Peer-review started: April 24, 2015
First decision: September 8, 2015
Revised: October 20, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: February 16, 2016
Processing time: 277 Days and 15.4 Hours
Core Tip
Core tip: Our paper reports a patient with plaque-type psoriasis and concomitant chronic hepatitis C virus (HCV), focusing on the safety and efficacy of cyclosporine therapy and anti tumor necrosis factors-α agents. This therapeutic association is also able to decrease liver enzymes as well as HCV load with general clinical improvement. Our topic may be useful in the clinical setting of patients with simultaneous severe psoriasis and chronic HCV infection.